14756-75-3

Usage

Uses

Used in Pharmaceutical Research:
THIENO[2,3-B]THIOPHENE-2-CARBOXYLIC ACID is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and potential biological activities. Its carboxylic acid functional group allows for easy modification and incorporation into drug molecules, enhancing their therapeutic properties.
Used in Organic Synthesis:
As a building block in organic synthesis, THIENO[2,3-B]THIOPHENE-2-CARBOXYLIC ACID is used to create a wide range of organic compounds with diverse applications. Its unique structure and functional group make it a valuable component in the development of new chemical entities and materials.
Used in Electronic Applications:
THIENO[2,3-B]THIOPHENE-2-CARBOXYLIC ACID is used as a key component in the development of organic electronic devices, such as organic light-emitting diodes (OLEDs) and organic solar cells. Its electronic properties and compatibility with other organic materials make it a promising candidate for improving the performance and efficiency of these devices.
Used in the Synthesis of Functional Materials:
THIENO[2,3-B]THIOPHENE-2-CARBOXYLIC ACID is utilized as a building block in the synthesis of functional materials with specific properties, such as conductivity, magnetism, or catalytic activity. Its unique structure and functional group contribute to the development of advanced materials for various applications, including sensors, catalysts, and energy storage devices.

InChI:InChI=1/C7H4O2S2/c8-6(9)5-3-4-1-2-10-7(4)11-5/h1-3H,(H,8,9)

Upstream product

• 39076-86-3 2-(1-oxoethyl)thieno<2,3-b>thiophene 
• 20969-37-3 methyl thieno[2,3-b]thiophene-2-carboxylate 
• 19685-82-6 methyl <(3-formylthiophene-2-yl)thio>acetate 
• 122267-20-3 methyl [3-(dioxolan-2-yl)-thiophen-2-ylthio]acetate 
• 13250-82-3 2-(thiophen-3-yl)-1,3-dioxolane 
• 498-62-4 3-thiophene carboxaldehyde 

Downstream Products

• 1026318-75-1 4-{2-[5-(2-benzenesulfonylamino-2-carboxy-ethylcarbamoyl)-thieno[2,3-b]thiophen-2-yl]-ethyl}-piperidine-1-carboxylic acid tert-butyl ester 
• 168157-23-1 4-(2-{5-[(S)-2-(3-Benzyl-ureido)-2-methoxycarbonyl-ethylcarbamoyl]-thieno[2,3-b]thiophen-2-yl}-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Small isomeric push-pull chromophores based on thienothiophenes with tunable optical (non)linearities

Fourteen new D-π-A push-pull chromophores based on two isomeric thienothiophene donors and seven acceptors of various electronic natures have been designed and conveniently synthesized. In contrast to known thienothiophene push-pull molecules, the prepared small chromophores proved to be organic materials with easily tunable thermal, electrochemical and (non)linear optical properties. It has also been shown that small structural variation may result in significantly improved/varied fundamental properties. Very detailed structure-property relationships were elucidated within the systematically developed series of push-pull molecules, which may serve as a useful guide in designing new D-π-A molecules based on fused thiophene scaffolds.

Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene α-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation

The synthesis and pharmacology of 4, a potent thienothiophene non- peptide fibrinogen receptor antagonist, are reported. Compound 4 inhibited the aggregation of human gel-filtered platelets with an IC50 of 8 nM and demonstrated an 8-fold improvement in affinity for isolated GPIIb/IIIa receptors over analogues possessing an isoindolinone backbone. Flow cytometry studies revealed that the binding of 4 to resting platelets is a diffusion- controlled process (k(on) = 3.3 x 106 M-1 s-1) and that 4 binds to dog and human platelets with comparable affinity (K(d) = 0.04 and 0.07 nM, respectively). Ex vivo platelet aggregation in dogs was completely inhibited by an iv dose of 5 mg/kg, and an oral dose of 50-90 mg/kg followed by low daily doses of 10 mg/kg was sufficient to maintain ~80% inhibition of ex vivo platelet aggregation over several days. Inhibition of ADP-induced platelet aggregation in anesthetized dogs at 77 ± 7% resulted in a moderate 2.5-fold increase in bleeding time, while complete inhibition (100%) resulted in an approximately 10-min bleeding time. Additional doses were required to increase the bleeding time to the maximum time allowed in the protocol (15 min), thus indicating a potentially useful and safe separation of efficacy and bleeding time.